바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.77 No.1
Citation Share

Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2014, v.77 no.1, pp.13-17







& (2014). Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution. Tuberculosis & Respiratory Diseases, 77(1), 13-17.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: This study analyzed the negative prognostic factors in patients who received second-line chemotherapy for advanced inoperable non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed the records of 137 patients with inoperable stage III−IV NSCLC who received second-line chemotherapy. The effects of clinical parameters on survival were analyzed and the hazard ratios (HR) for mortality were identified by a Cox regression analysis. Results: Sex, age older than 65 years, smoking history, cell type, T-stage, best response to first-line chemotherapy and first-line chemotherapy regimen were significant negative predictors in univariate analysis. The multivariate analysis showed that patients older than 65 years (HR, 1.530; 95% confidence interval [CI], 1.020−2.297), advanced T stage (T4 vs. T1; HR, 2.273; 95% CI, 1.010−5.114) and non-responders who showed progression with first-line chemotherapy (HR, 1.530; 95% CI, 1.063−2.203) had higher HR for death. Conclusion: The age factor, T stage and responsiveness to first-line chemotherapy were important factors in predicting the outcome of patients with advanced NSCLC who received second-line chemotherapy. The results may help to predict outcomes for these patients in the future.

keywords
Age Groups, Carcinoma, Non-Small-Cell Lung, Drug Therapy, Survival

Reference

1.

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.

2.

2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.

3.

3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.

4.

4. Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009;135:1596-609.

5.

5. Barlesi F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer 2006;51:159-72.

6.

6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.

7.

7. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy:a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010;46:735-43.

8.

8. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008;3:590-8.

9.

9. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-60.

10.

10. Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer 2012;77:116-20.

11.

11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

12.

12. Inal A, Kaplan MA, Kucukoner M, Urakci Z, Karakus A, Isikdogan A. Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev 2012;13:1281-4.

13.

13. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-11.

14.

14. Wu CH, Fan WC, Chen YM, Chou KT, Shih JF, Tsai CM, et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 2010;5:376-9.

15.

15. Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009;20:835-41.

16.

16. Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV nonsmall-cell lung cancer who failed first-line treatment. Br J Cancer 2005;92:15-20.

17.

17. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005;16:294-9.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy